Abstracts tagged "rheumatoid arthritis"

Abstract Number: 963 • 2018 ACR/ARHP Annual Meeting
Long-Term Safety of Tofacitinib up to 9.5 Years: A Comprehensive Integrated Analysis of the RA Clinical Development Program
Stanley Cohen¹, Yoshiya Tanaka², Xavier Mariette³, Jeffrey R. Curtis⁴, Eun Bong Lee⁵, Peter Nash⁶, Kevin Winthrop⁷, Christina Charles-Schoeman⁸, Lisy Wang⁹, Connie Chen¹⁰, Kenneth Kwok¹⁰, Pinaki Biswas¹⁰, Andrea Shapiro¹¹, Ann Madsen¹⁰ and Jürgen Wollenhaupt¹², ¹Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, ²University of Occupational and Environmental Health, Kitakyushu, Japan, ³Paris-Sud University, Le Kremlin Bicêtre, France, ⁴University of Alabama at Birmingham, Birmingham, AL, ⁵Seoul National University, Seoul, Korea, Republic of (South), ⁶University of Queensland, Brisbane, Australia, ⁷Oregon Health and Science University, Portland, OR, ⁸University of California, Los Angeles, CA, ⁹Pfizer Inc, Groton, CT, ¹⁰Pfizer Inc, New York, NY, ¹¹Pfizer Inc, Peapack, NJ, ¹²Schön-Klinik Hamburg-Eilbek Teaching Hospital of the University of Hamburg, Hamburg, Germany
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. Here, we report the largest integrated safety analysis of tofacitinib to date…
Abstract Number: 43 • 2018 ACR/ARHP Annual Meeting
Novel Anti-Malarial Drug Derivative Inhibited Anti-Citrullinated Protein/Peptide Antibodies and Rheumatoid Factors Production in Dnaseii/Ifnr Double Knock out Mice
Jie An¹, Bhanupriya Madarampalli², Xizhang Sun², Lena Tanaka³, Erika H. Noss², Joshua Woodward⁴, Tomikazu Sasaki⁵ and Keith B. Elkon⁶, ¹Division of Rheumatology, University of Washington, Seattle, WA, ²Rheumatology, University of Washington, Seattle, WA, ³Medicine/Rheumatology, University of Washington, Seattle, WA, ⁴Department of Microbiology, University of Washington, Seattle, WA, ⁵Department of Chemistry, University of Washington, Seattle, WA, ⁶University of Washington, Seattle, WA
Background/Purpose: Rheumatoid Arthritis (RA) is a highly prevalent autoimmune disease affecting ~1% of the world population and can lead to permanent joint damage and severe…
Abstract Number: 987 • 2018 ACR/ARHP Annual Meeting
CCL11 Is Involved in Cell Migration in Rheumatoid Arthritis
Kuninobu Wakabayashi, Takeo Isozaki, Shinichiro Nishimi and Tsuyoshi Kasama, Div of Rheumatology, Showa University School of Med, Shinagawa-ku Tokyo, Japan
Background/Purpose: Chemokine C-C motif ligand 11 (CCL11) also known as eotaxin-1 is produced by a variety of cell types. By interacting with C-C chemokine receptor…
Abstract Number: 47 • 2018 ACR/ARHP Annual Meeting
Analysis of the Role of RORγt+Foxp3+ T Regulatory 17 (Tr17) Cells in Murine Autoimmune Arthritis Model
Kotona Furuyama¹, Yuya Kondo¹, Masaru Shimizu², Iizuka Akira¹, Masahiro Yokosawa¹, Seiji Segawa¹, Hiroto Tsuboi¹, Isao Matsumoto¹ and Takayuki Sumida¹, ¹Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan, ²Internal Medicine, Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan
Background/Purpose: RORγt+Foxp3+ regulatory T (Treg) cells, designated as Tr17 is one of the new subset of Treg cells, having the potential to regulate the development…
Abstract Number: 1073 • 2018 ACR/ARHP Annual Meeting
Connective Tissue Growth Factor Associates with Angiogenesis through Notch-1 Activation in Rheumatoid Arthritis
Kazuhisa Nozawa¹, Takuya Hirai², Hiroshi Tsushima², Ken Yamaji³, Naoto Tamura³ and Iwao Sekigawa⁴, ¹2-1-1 Hongo Bunkyo-ku, Juntendo University, Tokyo, Japan, ²Rheumatology, Juntendo University Faculty of Medicine, Tokyo, Japan, ³Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan, ⁴Institute for Environment and Gender Specific Medicine, Juntendo University Graduate School of Medicine, Chiba, Japan
Background/Purpose: Aberrant angiogenesis has been considered as one of important factors for pathogenesis of rheumatoid arthritis (RA). Several angiogenetic mediators are reported to be massively…
Abstract Number: 50 • 2018 ACR/ARHP Annual Meeting
Intra-Articularly Delivering Lentivirus-Based CRISPR Interference Targeting Long Non-Coding RNA H19 in Synovial Fibroblasts Ameliorates Experimental Arthritis
Chrong-Reen Wang¹, Shih-Yao Chen², Yu-Ting Lo³, Yu-Chi Chou⁴, Ming-Fei Liu¹, Chao-Liang Wu⁵ and Ai-Li Shiau³, ¹Internal Medicine, National Cheng Kung University Hospital and Medical College, Tainan, Taiwan, ²Internal Medicine, National Cheng Kung University Hospital, Tainan, Taiwan, ³Microbiology and Immunology, National Cheng Kung University Medical College, Tainan, Taiwan, ⁴Core Facility for Manipulation of Gene Function, Academia Sinica, Taipei, Taiwan, ⁵Biochemistry and Molecular Biology, National Cheng Kung University Medical College, Tainan, Taiwan
Background/Purpose: Aberrantly higher expression of long non-coding RNAs (lncRNAs) in synovial fibroblasts (SFs) plays pathogenic roles in rheumatoid joint. Studying the effects on knocking down…
Abstract Number: 1076 • 2018 ACR/ARHP Annual Meeting
Phospholipase C-eta2, As a C2 Domain-Containing Protein, Regulate Aggressiveness of Fibroblast‐like Synoviocytes and Ameliorate Arthritis in Experimental Animal Models of Rheumatoid Arthritis
Mingyo Kim, Hyun Min Jeon, Hae Sook Noh, Sang Mi Yi and Sang-Il Lee, Department of Internal Medicine and Institute of Health Science, Gyeongsang National University School of Medicine, Jinju, Korea, Republic of (South)
Background/Purpose: The C2 domain is a Ca2+-dependent membrane-targeting motif found in many cellular proteins involved in signal transduction or inflammatory pathway. However, the effects of…
Abstract Number: 53 • 2018 ACR/ARHP Annual Meeting
Cyclin-Dependent Kinase 4/6 Inhibitor: A Promising Development Candidate Targeting Synovial Hypertrophy for Rheumatoid Arthritis Treatment
Shunsuke Tsujimoto, Kyohei Horie, Toshiya Mashiko, Johji Nomura and Tsunefumi Kobayashi, Teijin Institute for Bio-medical Research, TEIJIN PHARMA LIMITED, Tokyo, Japan
Background/Purpose: The pathogenesis of rheumatoid arthritis (RA) is characterized by the infiltration of immune cells into the synovial tissues and the hypertrophy of synovial fibroblasts,…
Abstract Number: 1201 • 2018 ACR/ARHP Annual Meeting
Finger Extensor Tendon Involvement Is Frequent in Early Rheumatoid Arthritis
Mihaela Maruseac¹, Patrick Durez^2,3, Adrien Nzeusseu Toukap⁴ and Maria Stoenoiu⁵, ¹Rheumatology, Cliniques Universitaires Saint-Luc, Brussels, Belgium, ²Pôle de Maladies Rhumatismales, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels, Belgium, ³Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, Université Catholique de Louvain, Brussels, Belgium, ⁴Department of Rheumatology, Rheumatology - Cliniques universitaires Saint-Luc - Université Catholique de Louvain - Institut de Recherche Expérimentale et Clinique (IREC), Brussels, Belgium, ⁵Rheumatology, Cliniques Universitaires Saint-Luc, Institut de Recherche Expérimentale et Clinique (IREC), Brussels, Belgium
Background/Purpose: Finger extensor involvement (FET) at ultrasound examination (US) was previously described in patients suffering from early psoriatic arthritis. Contradictory results were published in patients…
Abstract Number: 55 • 2018 ACR/ARHP Annual Meeting
Adipose Derived Stem Cell Suppressed Synovial Inflammation and Repaired Cartilage Destruction in Rheumatoid Arthritis Model Mice
Tadashi Okano¹, Kentaro Inui², Hideki Ueyama³, Kumi Orita³, Tatsuya Koike⁴ and Hiroaki Nakamura², ¹Orthopedic Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan, ²Orthopaedic Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan, ³Osaka City University Graduate School of Medicine, Osaka, Japan, ⁴Center for Senile Degenerative Disorders, Osaka City University Graduate School of Medicine, Osaka, Japan
Background/Purpose: Adipose derived stem cell (ADSC) is one of the stem cells produced by adipose tissue which can be collected easily and in large quantities.…
Abstract Number: 1519 • 2018 ACR/ARHP Annual Meeting
Patient Characteristics Associated with Discontinuation of Tofacitinib for the Treatment of Rheumatoid Arthritis in Open-Label, Long-Term Extension Studies up to 9.5 Years
Jeffrey R. Curtis¹, Jürgen Wollenhaupt², Katerina Chatzidionysiou³, Sander W. Tas⁴, Lisy Wang⁵, Harry Shi⁶, María Montoro⁷, Petra Neregård⁸, Palle Dahl⁹ and Vassilis Tsekouras¹⁰, ¹University of Alabama at Birmingham, Birmingham, AL, ²Schön Klinik Hamburg-Eilbek Teaching Hospital of the University of Hamburg, Hamburg, Germany, ³Division of Rheumatology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, ⁴Amsterdam Rheumatology and Immunology Center, Academic Medical Center, Amsterdam, Netherlands, ⁵Pfizer Inc, Groton, CT, ⁶Pfizer Inc, Collegeville, PA, ⁷Pfizer Inc, Madrid, Spain, ⁸Pfizer Inc, Stochholm, Sweden, ⁹Pfizer Inc, Ballerup, Denmark, ¹⁰Pfizer Inc, Athens, Greece
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. We explored characteristics of patients (pts) who discontinued (d/c) open-label, long-term extension…
Abstract Number: 59 • 2018 ACR/ARHP Annual Meeting
Elucidating the Expression and Role of Heparan Sulfate Proteoglycan Editing Sulfatases in Human Rheumatoid Arthritis Synovium and a Rat Adjuvant-Induced Arthritis Model
Ruby J. Siegel¹, Solomon A. Agere¹, Anil K. Singh¹ and Salahuddin Ahmed^2,3, ¹Washington State University, Department of Pharmaceutical Sciences, College of Pharmacy, Spokane, WA, ²Department of Pharmaceutical Sciences, Washington State University, College of Pharmacy, Spokane, WA, ³Division of Rheumatology, University of Washington, Division of Rheumatology, School of Medicine, Seattle, WA
Background/Purpose: Syndecans are cell-surface heparan sulfate proteoglycans (HSPGs) that modulate the receptor/ligand binding of chemokines, cytokines, and growth factors in order to facilitate cellular signaling.…
Abstract Number: 1526 • 2018 ACR/ARHP Annual Meeting
Baseline Characteristics and Outcomes in Patients with Anemia in Clinical Studies of Tofacitinib
Burkhard Moeller¹, Axel Finckh², Jose Maria Alvaro-Gracia³, Godehard Scholz¹, Daniel Aletaha⁴, Francesca Biondo⁵, Sander Strengholt⁶, Jose L Rivas⁷, Carol A Connell⁸ and Harry Shi⁹, ¹Inselspital-University Hospital, Bern, Switzerland, ²University Hospital of Geneva, Geneva, Switzerland, ³Hospital Universitario de La Princesa, Madrid, Spain, ⁴Medical University of Vienna, Vienna, Austria, ⁵Pfizer Inc, Rome, Italy, ⁶Pfizer Inc, Capelle aan den IJssel, Netherlands, ⁷Pfizer SLU, Madrid, Spain, ⁸Pfizer Inc, Groton, CT, ⁹Pfizer Inc, Collegeville, PA
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. The purpose of this study is to describe the profile of patients…
Abstract Number: 64 • 2018 ACR/ARHP Annual Meeting
Dietary Magnesium Modulates the Intestinal Microbiome and T Cell Subsets
Teresina Laragione¹, Carolyn Harris¹ and Percio S. Gulko², ¹Medicine/Rheumatology, Icahn School of Medicine at Mount Sinai, New York, NY, ²Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY
Background/Purpose: Several studies have demonstrated that Magnesium (Mg) has a key role in the immune responses. Our previous studies showed that a short-term low Mg…
Abstract Number: 1981 • 2018 ACR/ARHP Annual Meeting
A Molecular Bayesian Network for Rheumatoid Arthritis Reveals Multiple Candidate Key Regulators for Disease Severity
Wenhui Wang¹, Amit Lahiri², Teresina Laragione², Jun Zhu¹ and Percio S. Gulko^2,3, ¹Genetics and Genomics, Icahn School of Medicine at Mount Sinai, New York, NY, ²Medicine/Rheumatology, Icahn School of Medicine at Mount Sinai, New York, NY, ³Icahn School of Medicine at Mount Sinai, New York, NY
Background/Purpose: Rheumatoid arthritis (RA) is a common and chronic autoimmune joint disease. RA is pathologically heterogeneous with multiple contributing factors. While there has been a…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].